logo
Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week ® 2025

Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week ® 2025

Business Wire06-05-2025
PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio ®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced completion of the largest annual pancreatic cyst consortium held at the Digestive Disease Week ® (DDW) Conference in San Diego, California, on Monday May 5, 2025. The detailed program is available on the Mauna Kea Technologies website at the following link:
https://www.landing.maunakeatech.com/hubfs/ddw/DDW_2025_Consortium_Agenda.pdf
The consortium brought together more than 75 physicians from across the United States with a focus on cutting-edge advancements in the diagnosis, classification, risk stratification, and treatment of pancreatic cystic lesions and pancreatic cancer. Attendance tripled compared to the 2024 meeting, reflecting the growing interest among the medical community in this field. Central to the discussions was the growing impact of endoscopic ultrasound with Cellvizio needle-based Confocal Laser Endomicroscopy (EUS-nCLE) in enabling earlier and more accurate diagnoses and clinical decisions before any therapy begins, with the goal of increasing non-surgical treatment options.
The consortium was led by Dr. Somashekar (Som) Krishna, MD, MPH, Professor of Medicine and Director of Advanced Endoscopy at The Ohio State University Wexner Medical Center and principal investigator of the CLIMB 1 study. It was co-sponsored by 9 leading medical device and pharmaceutical products companies, demonstrating strong cross-industry commitment to advancing care for the millions of patients affected by pancreatic cystic lesions worldwide.
"This year's consortium marks a turning point in how the medical community and the industry approach pancreatic cyst management and treatment,' said Sacha Loiseau, Ph.D., Chairman and Chief Executive Officer of Mauna Kea Technologies. 'Bringing together more than 75 top physicians and 9 committed industry partners shows that the ecosystem around EUS-nCLE, RFA 2, and AI is maturing rapidly - and with it, our ability to change the standard of care for patients facing pancreatic lesions. A clear momentum is building around this application, driven by the recent endorsement of nCLE in European clinical guidelines and the surge of interest we're now seeing in the United States at DDW. We're proud to help lead this transformation and deeply grateful to our collaborators and clinical pioneers who are making it possible. With Cellvizio, we are targeting one of the largest unmet clinical issues in gastroenterology - and changing the trajectory for many patients at risk of pancreatic cancer.'
***
About Pancreatic Cysts
The prevalence of pancreatic cystic lesions in the adult asymptomatic population ranges from 2.4% to 24.3%. The large majority of pancreatic cystic lesions are discovered through incidental imaging, and it is estimated that 40% of cysts with no risk of carcinogenesis are operated on unnecessarily. More accurate classification methods, including risk stratification, are therefore needed earlier in the patient's diagnostic workup. Conventional diagnostic testing involves performing an endoscopic ultrasound (EUS) and then collecting and testing the cyst fluid through fine needle aspiration (FNA). In some advanced facilities, next generation sequencing (NGS) of cellular DNA may be performed to provide additional data. Although most facilities employ a combination of a range of conventional diagnostic methods, sensitivity, specificity, and accuracy remain insufficient, potentially exposing patients to misclassified cysts and unneeded surgical procedures.
About Digestive Disease Week ®
Digestive Disease Week ® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW was an in-person and online meeting from May 3-6, 2025. The meeting showcases more than 5,600 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio ®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio ® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.
Disclaimer
This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2024 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2025, which is available on the Company's website (www.maunakeatech.fr), as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.
_________________________________
1 ClinicalTrials.gov: NCT03492151
2 Radiofrequency Ablation
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

time2 days ago

  • Business Wire

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation ('Quanterix' or the 'Company') (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that on July 8, 2025, the Company approved inducement grants of restricted stock units ('RSUs') representing 267,269 shares of Quanterix common stock to twenty employees newly-hired in connection with the acquisition of Akoya Biosciences, Inc. The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company. The RSUs vest in full on the one year anniversary of the grant date, subject to the applicable individual's continued employment with the Company or one of its subsidiaries through the vesting date. About Quanterix Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa ® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company ®, adding multiplexed tissue imaging with single-cell resolution to its portfolio. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at

S&P Recognizes Southern New Hampshire Health's Strong Financial Position
S&P Recognizes Southern New Hampshire Health's Strong Financial Position

Business Wire

time2 days ago

  • Business Wire

S&P Recognizes Southern New Hampshire Health's Strong Financial Position

NASHUA, N.H.--(BUSINESS WIRE)--S&P Global Ratings announced today that it has affirmed an 'A-' rating for Southern New Hampshire Health, continuing the system's highest ever rating. The S&P report reflects the system's growing patient volumes, stable operating performance and solid financial profile. S&P noted Southern New Hampshire Health's stable outlook, recognizing improvement in financial performance. 'We're excited that S&P has affirmed our A- rating,' said Ken Matsis, Chief Financial Officer of Southern New Hampshire Health. 'This rating is recognition of the hard work we have put in to improve operating performance and is an indication of our strong financial profile and opportunity for future success.' Key report findings: Financial Stability: Demonstrates a strong financial profile, with improvement in operating margins, a very healthy debt profile, growing reserves and a healthy balance sheet, all showing improved earnings. Market Position: Growing patient volumes in a competitive marketplace, with further anticipated growth from specialty services and core service areas. Operating Performance: Ongoing investments in facility upgrades and technological advancements tied to the heart and vascular center. Strong Leadership: Continued focus by management on strategic growth initiatives and targeted improvements in efficiency, throughput and resource allocation generate financial success. 'This rating acknowledges our strong performance over the past two years,' said Colin T. McHugh, President and Chief Executive Officer of Southern New Hampshire Health. 'S&P's evaluation of our improved operating trend and strategic growth in core services and expanded access to care shows our commitment to being the top local healthcare provider.' As a non-profit, mission-driven healthcare system committed to improving health outcomes, Southern New Hampshire Health reinvests its profits back into healthcare services. Their focus is on delivering high-quality, accessible care to the patients and communities served by the system. ### About Southern New Hampshire Health: Southern New Hampshire Health (SNHH) is comprised of Southern New Hampshire Medical Center (SNHMC) and Foundation Medical Partners, and is Massachusetts General Hospital's first clinical affiliate in the region. SNHMC is a 188-bed facility that has two campuses in Nashua. Southern New Hampshire Medical Center has been recognized by the American Nurses Credentialing Center as a Magnet® hospital and is in the top 1% of hospitals in the country to achieve four designations, illustrating its dedication to excellence in nursing. Foundation Medical Partners is a multi-specialty physician group with more than 300 primary care and specialty care providers. SNHH is committed to improving, maintaining, and preserving the overall health and well-being of individuals living in the greater Nashua area by providing information, education, and access to exceptional health care services. Learn more at

CareView Communications Launches Partnership with Memorial Hospital Biloxi to Enhance Virtual Sitting Services
CareView Communications Launches Partnership with Memorial Hospital Biloxi to Enhance Virtual Sitting Services

Business Wire

time2 days ago

  • Business Wire

CareView Communications Launches Partnership with Memorial Hospital Biloxi to Enhance Virtual Sitting Services

LEWISVILLE, Texas--(BUSINESS WIRE)--CareView Communications, Inc., a leading provider of virtual care and patient monitoring solutions ('CareView' or the 'Company') (OTCQB: CRVW), is proud to announce a new partnership with Memorial Hospital Biloxi to improve patient care through advanced virtual sitting technology. This collaboration allows Memorial Hospital Biloxi to leverage CareView's latest state-of-the-art platform. This platform uses predictive technology to enhance care coordination, reduce patient risk, and empower clinical teams to observe patients in real-time from a centralized location. The partnership reflects a shared commitment to delivering high-quality, technology-enabled care to patients across the Gulf Coast region. 'We are excited to partner with Memorial Hospital Biloxi, an organization that shares our passion for patient-centered innovation,' said Sandra McRee, Chief Operating Officer at CareView Communications. 'Together, we will expand access to care, improve clinical outcomes, and support patients by providing enhanced observation and safety through our virtual sitting solution.' CareView's solutions provide real-time visual monitoring, fall-risk alerts, and communication tools that enable staff to intervene quickly and proactively. This information enables Memorial Hospital Biloxi's care teams to reduce adverse events, optimize staffing, and ensure a safer patient environment. Implementing CareView's technology is part of Memorial Hospital Biloxi's broader initiative to invest in digital health solutions that improve operational efficiency while maintaining the highest standards of patient care. For more information about CareView's virtual care solutions, visit About CareView Communications Inc. CareView has been dedicated to supporting hospital care teams for over a decade with its innovative virtual care solutions. The Company has established successful partnerships with over 200 hospitals nationwide, implementing effective inpatient virtual care strategies that greatly enhance patient safety and overcome critical staffing challenges. The CareView platform, fueled by industry-leading predictive technology and supported by its purpose-built hardware, specifically addresses the unique requirements of virtual nursing and virtual sitting use cases. The CareView team works closely with their hospital partners to understand their evolving needs and deliver tailored virtual care strategies that align with their objectives. By providing healthcare professionals with the tools they need to deliver exceptional care, CareView contributes to improved patient outcomes and a more sustainable healthcare ecosystem. Learn more at or follow CareView on LinkedIn. About Memorial Hospital Biloxi Memorial Hospital Biloxi is a not-for-profit, multi-facility healthcare system serving the Mississippi Gulf Coast. With a commitment to excellence, innovation, and community care, Memorial provides a comprehensive range of medical services, including advanced primary and specialty care, across its network of providers and facilities.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store